Proundly Supported by
Pfizer Foundation
    Home | Current Issue | Past Issue | Board | Instruction | Contact


Adverse affects of Paclitaxel and Carboplatin Combination Chemotherapy in Epithelial Gynecologic Cancer

301

Chumnan Kietpeerakool, MD*,
Prapaporn Suprasert, MD*, Jatupol Srisomboon, MD*

* Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai

Abstract


Objective: To evaluate the adverse affects of paclitaxel and carboplatin combination chemotherapy.
Design: Descriptive cross sectional study
Material and Method: Patients with epithelial cancer of the ovary, fallopian tube and peritoneum treated with paclitaxel and carboplatin combination chemotherapy at Chiang Mai University Hospital between August 2003 and August 2004.
Results: Of 224 evaluable cycles in 63 patients treated with paclitaxel (175 mg/m2) and carboplatin (AUC 5), grade 3 and 4 neutropenia occurred in 37.1% or 41.3% of patients. 4.8% of patients experienced febrile neutropenia. Grade 3 and 4 leukopenia occurred in 8.6% of courses and 12.6% of patients. Grade 3 anemia occurred in 5.2% of courses and 9.5% of patients. Grade 3 thrombocytopenia occurred in 2.8% of courses and 9.6% of patients. The nonhematologic adverse affects were rare, however, some adverse events may be potentially life threatening.
Conclusion: Adverse affects of paclitaxel and carboplatin combination chemotherapy are acceptable and manageable in the majority of patients.

Keyword : Adverse affects, Paclitaxel, Carboplatin, Epithelial gynecologic cancer



Download Full Paper
  Vol88_No3_301.pdf  [ 81.63 Kb]

Home | Current Issue | Past Issue | Board | Instruction | Contact

© Copyright The Medical Association of Thailand. All Rights Reserved.2001-2002